Regulatory Insights

  1. Who Decides? Navigating AI Governance in Clinical Research 6/15/2026

    AI in clinical research poses governance challenges. Clear ownership, consistent policies, and aligned teams help manage risk, ensure compliance, and drive responsible innovation in complex trials.

  2. Building A Clinical Research AI Governance Framework 6/15/2026

    Learn how structured oversight, transparency, and collaboration help ensure compliance, reduce bias, and build trust while enabling innovation in increasingly data-driven trials.

  3. TrialScope EXTRA Keynotes Address Data Ownership, Health Communication 6/11/2026

    Can your regulatory and protocol strategies keep pace with evolving data ownership, disclosure, and AI requirements? Explore key compliance risks, protections, and practical solutions.

  4. 2026 Clinical Trials: Strong Headwinds, Winds Of Change 6/11/2026

    Are your Phase I–III/IV clinical studies prepared for today's regulatory landscape? Learn how leading organizations are addressing compliance, transparency, and data ownership risks.

  5. Barcode-Driven Verification: Enhancing Compliance 6/10/2026

    Investigational products present a distinctly high-risk environment for labeling and barcoding. Explore best practices for barcoding solutions that allow for improved medication safety in clinical trials.

  6. How Remote Pharmacy Monitoring Improves Trial Compliance 6/10/2026

    Explore how leading IDS pharmacies are using remote monitoring workflows and digital accountability systems to improve accuracy, reduce site burden, and maintain audit readiness.

  7. Successful SwissMedic Marketing Authorization Application For An Oncology Therapy 6/4/2026

    See how strategic EU dossier adaptation and Swiss-specific regulatory expertise enabled a successful SwissMedic submission and accelerated market access for an oncology therapy.

  8. FDA Expedited Programs – What You Need To Know 6/4/2026

    Explore FDA expedited programs and learn how Fast Track, Breakthrough Therapy, RMAT, Priority Review, and more can help accelerate development and bring therapies to patients sooner.

  9. End-To-End Clinical, Biometrics, And Regulatory Support In Neurology 6/4/2026

    Discover how an integrated NDA strategy aligned data, vendors, and regulatory execution to achieve an on-time submission and approval without major FDA queries.

  10. Ethical & Regulatory Considerations For Pediatric Gene Therapy 5/28/2026

    Understanding risk thresholds, consent requirements, and IRB expectations early can prevent redesign, reduce delays, and improve trial feasibility for vulnerable patient populations